A little more on Tensha, which is Jay Bradner's former company now acquired by Roche.

This is from a 2012 Nature Biotech article. "Tensha says that it is moving forward with a clinical candidate chosen from about 500 molecules in and around the JQ1 chemical space. Although it's too soon to reveal their clinical development strategy, Bradner notes that bromodomain inhibition could be broadly applicable outside oncology." That was back in 2012.

Although RVX/Zenith like to talk about their head start over the competition, there is clearly a lot of BET inhibitor work going on in big pharma. BKC posted on the RVX board last week "Glaxosmithkline and the likes are working on BET inhibition (admittedly mostly for oncology, but inflammation is also on the list). Actually, Glaxosmithkline had an interesting patent application published today on compounds that inhibit the "the first and/or second bromodomains of human BRD-2 to 4". A lot of BET inhibition work is going on in big pharma......"

Also, I really like the last sentence in the JQ1/PD-L1 article i posted yesterday: "Given the demonstrated broad applicability of PD-L1 blockade therapy in human cancer, we anticipate our findings [BET inhibitors] to have far-reaching implications for developing future combinatory cancer therapies."